Catalyst Pharmaceuticals (CPRX) Q4 2024 earnings summary

Executive summary

• Achieved record 2024 revenues of $491.7 million, up 23.5% year-over-year, driven by strong commercial performance of Firdapse, Fycompa, and the successful launch of Agamree.

• Q4 2024 revenues reached $141.8 million, a 28.3% increase year-over-year, reflecting sustained organic growth and accelerating Agamree adoption.

• Ended 2024 with $517.6 million in cash and no debt, providing significant flexibility for strategic investments.

• Strategic focus on rare diseases, patient engagement, and expanding international presence, including launches in Japan and pending submissions in Canada.

• Strategic investments and partnerships expanded market presence, including Agamree's U.S. launch and Firdapse's approval in Japan.

Financial highlights

• Full year 2024 net product revenue was $489.3 million (+23.4% YoY); Q4 2024 net product revenue was $141.8 million (+30% YoY).

• Firdapse 2024 revenue: $306 million (+18.4% YoY); Agamree: $46 million (first year); Fycompa: $137.3 million.

• U.S. GAAP net income for 2024 was $163.9 million ($1.38 basic, $1.31 diluted EPS), up 130% year-over-year.

• Non-GAAP net income for 2024 was $276.3 million ($2.33 basic, $2.21 diluted EPS), a 95% increase year-over-year.

• Cash and cash equivalents at year-end: $517.6 million, up from $137.6 million in 2023.

Outlook and guidance

• 2025 total revenue forecasted at $545–$565 million, reflecting continued growth.

• Firdapse 2025 net product revenue expected at $355–$360 million, factoring in IRA-related gross-to-net increases.

• Agamree 2025 net product revenue projected at $100–$110 million; Fycompa at $90–$95 million, reflecting anticipated generic entry.

• R&D expenses for 2025 forecasted at $15–$20 million; SG&A expected to rise with expanded field forces.